Canaan Inc. received a formal Nasdaq notification after its American depositary shares traded below the $1.00 minimum bid price for 30 consecutive business days, according to the exchange. The notice, issued on January 14, 2026, starts a 180-calendar-day compliance window under Nasdaq Listing Rule 5550(a)(2).
The warning does not halt trading, but it places the company on a defined timetable with clear capital-markets implications if the bid-price requirement is not cured. In practical terms, the letter turns share-price recovery into an operational milestone with financing and visibility consequences.
Compliance Timeline and Cure Requirements
Nasdaq’s deficiency letter cited failure to meet the minimum bid-price requirement and gave Canaan until July 13, 2026 to regain compliance. To cure the deficiency in the initial window, the closing bid price must be at least $1.00 for a minimum of 10 consecutive trading days under Nasdaq Listing Rule 5810(c)(3)(A).
If Canaan does not meet the standard by the July deadline, Nasdaq may grant an additional 180-day extension at its discretion. To qualify, Canaan would need to submit a Transfer Application, pay a non-refundable $5,000 fee, demonstrate it meets other initial listing criteria aside from bid price, and provide a plan—commonly a reverse stock split—to remedy the deficiency.
Canaan said it will monitor share performance and consider “all reasonable measures” to regain compliance, including a reverse stock split. While a reverse split can mechanically lift the per-share price by consolidating shares, the text emphasizes it does not change enterprise value and is often viewed as cosmetic by market participants.
Market and Strategic Implications
A failure to regain compliance would likely push trading to OTC venues such as the OTC Bulletin Board or Pink Sheets. The described consequence set includes reduced liquidity and visibility, a more difficult environment for capital raises and institutional participation, and potentially higher volatility for retail holders.
Analyst coverage was described as mixed but tilted optimistic, with consensus ratings often clustering near “Strong Buy” and average 12-month targets cited roughly between $2.85 and $5.95. Forecasts referenced in the same context ranged from about $1.75 to $8.00, underscoring wide dispersion relative to current price levels.
The broader sector backdrop adds another layer to the risk picture, with mining peers pursuing diversification into AI and high-performance computing and securing multi-year contracts with large cloud providers. The framing implies that meeting Nasdaq’s bid-price rule is necessary for listing status but does not resolve underlying questions about revenue mix and partnerships.
Investors will now focus on execution against the clock: pushing the ADS price above $1.00 for the required 10 consecutive trading days before July 13, 2026, or pursuing an extension supported by a credible cure plan. Failure on either path would shift the stock off Nasdaq and materially alter Canaan’s financing options and investor base.